0.50Open0.50Pre Close0 Volume9 Open Interest129.00Strike Price0.00Turnover3998.40%IV4.83%PremiumMay 2, 2025Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type0.1714Delta0.0457Gamma247.06Leverage Ratio-1528.5717Theta0.0000Rho42.35Eff Leverage0.0004Vega
Biogen Stock Discussion
Breakthrough: First-Ever Drug to Slow Early Alzheimer's Gets EU Green Light
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal
Biogen's Bold Move: 580,000 sq ft Innovation Powerhouse to Transform Kendall Square Research Hub
Biogen's Breakthrough Drug Enters Final Testing Phase for Critical Kidney Transplant Complication
Market worries over the tariffs focus on two key issues. U.S. companies that depend heavily ...
No comment yet